Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
Wipfler P, et al. Among authors: oppermann k.
Mult Scler. 2011 Jan;17(1):16-23. doi: 10.1177/1352458510383075. Epub 2010 Oct 11.
Mult Scler. 2011.
PMID: 20937631